Loading
PRKAR1A (cAMP-dependent protein kinase type I-alpha regulatory subunit) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Adrenocortical carcinoma, Thyroid cancer, Renal cell carcinoma and 2 more.
Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signalling in cells.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.81 (direct and indirect evidence; datatypes genetic literature 0.85, affected pathway 0.83, literature 0.86, genetic association 0.01, somatic mutation 0.85, animal model 0.73). IntOGen calls it a driver in 4 cohorts (2 activating, 2 loss-of-function), covering Adrenocortical Carcinoma, Medulloblastoma, Pilocytic Astrocytoma.
In plain words · PRKAR1A (cAMP-dependent protein kinase type I-alpha regulatory subunit) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Adrenocortical carcinoma, Thyroid cancer, Renal cell carcinoma and 2 more.
PRKAR1A (cAMP-dependent protein kinase type I-alpha regulatory subunit) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Adrenocortical carcinoma, Thyroid cancer, Renal cell carcinoma and 2 more.
Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signalling in cells. Location: Cell membrane (UniProt).
No product in this corpus aims at PRKAR1A yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA PRKAR1A: RNA low tissue specificity; no normal tissue stained high; highest cancer staining melanoma (1 of 11 high). Distribution: 4 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Adrenocortical carcinoma, Thyroid cancer, Renal cell carcinoma, Brain and spinal cord tumours (all types)); Open Targets associates it with 2 specific cancer types at or above 0.5 (familial atrial myxoma, hereditary neoplastic syndrome). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P10644; CIViC gene PRKAR1A; IntOGen PRKAR1A; Human Protein Atlas PRKAR1A tissue; Open Targets ENSG00000108946 associations
First described 1987. Earliest sequence paper UniProt cites for the protein: Sandberg et al, Biochem. Biophys. Res. Commun, 1987, "Molecular cloning, cDNA structure and deduced amino acid sequence for a type I regulatory subunit of cAMP-dependent protein kinase from human testis". Source.
Sources: HGNC HGNC:9388 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P10644 (protein name, function text, keywords and locations (REST API)); CIViC gene PRKAR1A (1 evidence items, 0 assertions, 1 variants; diseases: Melanotic Neurilemmoma (GraphQL API, CC0)); Open Targets ENSG00000108946 (association with cancer (MONDO_0004992) 0.81; per-cancer scores at or above 0.5: renal cell carcinoma 0.52, thyroid cancer 0.54 (GraphQL API, CC0)); IntOGen PRKAR1A (driver in 4 cohorts (Act 2, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signalling in cells. Location: Cell membrane (UniProt). Locus 17q24.2 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high; medium in Adrenal gland, Cerebral cortex, Cervix, Colon, Endometrium, Heart muscle and more.
Medium only: breast cancer, carcinoid, cervical cancer, colorectal cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PRKAR1A" OR ABSTRACT:"PRKAR1A" OR TITLE:"protein kinase cAMP-dependent type I regulatory subunit alpha" OR ABSTRACT:"protein kinase cAMP-dependent type I regulatory subunit alpha" OR TITLE:"cAMP-dependent protein kinase type I-alpha regulatory subunit" OR ABSTRACT:"cAMP-dependent protein kinase type I-alpha regulatory subunit" OR TITLE:"CNC1" OR ABSTRACT:"CNC1" OR TITLE:"PRKAR1" OR ABSTRACT:"PRKAR1" OR TITLE:"TSE1" OR ABSTRACT:"TSE1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PRKAR1A, not a curated reading list.
Shares Paediatric low-grade glioma, Medulloblastoma, IntOGen.
Shares Paediatric low-grade glioma, Medulloblastoma, IntOGen.
Shares Paediatric low-grade glioma, Medulloblastoma, IntOGen.
Shares Paediatric low-grade glioma, Medulloblastoma, IntOGen.
Shares Adrenocortical carcinoma, IntOGen, Open Targets Platform.
Shares Thyroid cancer, CIViC, Open Targets Platform.
Shares Thyroid cancer, Renal cell carcinoma, CIViC, IntOGen.
Shares Paediatric low-grade glioma, Medulloblastoma, CIViC, IntOGen.